From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

Last Updated: Thursday, May 15, 2025

A case study of a patient with HR+ HER2- breast cancer with a MammaPrint gene signature indicating a very high risk of recurrence. The patient was treated with a triple-negative breast cancer protocol, and she achieved a complete response. She remains disease free after 2 years, with ongoing follow-up.

npj Precision Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement